

Reduced IL-37 gene expression and CD8 T lymphocytes in patients with metastatic breast cancer

Najmeh Farahani^{1*}, Fathollah Mohagheghi², Ghasem Mosayebi^{1,3}, Ali Ghazavi^{1,4}, Ali Ganji^{1,3}

¹ *Department of Immunology & Microbiology, School of Medicine, Arak University of Medical Sciences, Arak, Iran*

² *Department of Radiotherapy and Oncology, Arak University of Medical Sciences, Arak, Iran*

³ *Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran*

⁴ *Traditional and Complementary Medicine Research Center (TCMRC), Arak University of Medical*

Received January 31,2022; Accepted February 10,2022; Published online April 10,2022

Abstract

The exact immunopathological mechanisms in the progression of breast cancer are not clearly understood, but various factors including CD8 T lymphocytes have lethal properties on tumor cells. On the other hand, interleukin-37 (IL-37), as a new member of the IL-1 family, is an anti-inflammatory cytokine. The exact role of IL-37 in breast cancer has not yet been determined. This study aimed to evaluate the CD8 T lymphocytes count and IL-37 gene expression in newly diagnosed breast cancer patients with and without metastasis. In this study, blood samples from 36 metastatic and 36 non-metastatic breast cancer patients and 36 healthy individuals as control were collected. After RNA extraction and cDNA synthesis, the relative gene expression was performed using real-time PCR. Also, counting the CD8 T lymphocytes was done by flow cytometry technique. The results of this study showed that the gene expression of IL-37 in blood samples of metastatic and non-metastatic breast cancer patients was significantly lower than in healthy individuals ($P < 0.05$). The relative gene expression of the IL-37 in ER+/PR+/HER2+ patients with non-metastatic breast cancer had a significant increase compared to HER2+ patients ($P < 0.05$). Also, CD8 T lymphocytes count in the samples of patients including non-metastatic and metastatic breast cancer was significantly decreased compared to the healthy individuals ($P < 0.05$). Our findings provide evidence that IL-37 gene expression and CD8 T lymphocytes count, significantly decreased in non-metastatic and metastatic breast cancer. Considering the possible effects of IL-37 on TCD8 cells in tumor

*e-mail: najmeh.far1358@yahoo.com

immune responses, more research will be done to benefit from the therapeutic effects of this cytokine in the future.

Keywords: CD8 T lymphocytes, IL-37, Metastatic breast cancer

Acknowledgments

This research was supported by Deputy of Research Affairs, School of Medicine, Arak University of Medical Sciences, Iran.

Conflict of interests

The authors have no conflicts of interest to declare.